Constellation Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference

CAMBRIDGE, Mass.--()--Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics, today announced that President and Chief Executive Officer Jigar Raythatha will present a company overview at the Oppenheimer & Co. Inc. 28th Annual Healthcare Conference on March 21 at 3:20 p.m. EDT in the Track 3 room. The conference is being held March 20-21 at the Westin New York Grand Central in New York, NY.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel small molecule therapies based on its pioneering research in cancer epigenetics. With a decade of experience in the field, the company has an unparalleled understanding of how epigenetic regulators modulate gene expression in cancer cells and in the tumor and immune microenvironment. Constellation is translating these insights to advance the company’s two lead clinical programs, CPI-1205 and CPI-0610, and in novel targets for which cancer epigenetics may help enhance response over currently available treatment options.

For more information, please visit www.constellationpharma.com.

Contacts

Media contact:
W2O Group
Katie Engleman, +1-910-509-3977
kengleman@w2ogroup.com
or
Investor contact:
Stern Investor Relations, Inc.
Stephanie Ascher, +1-212-362-1200
stephanie@sternir.com

Contacts

Media contact:
W2O Group
Katie Engleman, +1-910-509-3977
kengleman@w2ogroup.com
or
Investor contact:
Stern Investor Relations, Inc.
Stephanie Ascher, +1-212-362-1200
stephanie@sternir.com